Longhurst HJ, et al. - Researchers performed retrospective analyses using data from the Icatibant Outcome Survey (IOS; Shire, Zug, Switzerland), an international observational study monitoring safety and effectiveness of icatibant (a selective bradykinin B2 receptor antagonist), to study the clinical profile, management and outcomes of patients with hereditary angioedema (HAE) type I and II from three specialist centres in the UK. They analyzed overall 73 UK and 579 non-UK patients with HAE type I or II. Findings showed similar diagnostic delay and similar icatibant treatment outcomes for UK patients from the specialist centres vs their non-UK counterparts. However, still, there is a need for improvements in the timely diagnosis of HAE.